HomeComparePMPEX vs ABBV

PMPEX vs ABBV: Dividend Comparison 2026

PMPEX yields 12.99% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $57.7K in total portfolio value· pulled ahead in Year 5
10 years
PMPEX
PMPEX
● Live price
12.99%
Share price
$15.40
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.0K
Annual income
$2,912.61
Full PMPEX calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — PMPEX vs ABBV

📍 ABBV pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPMPEXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PMPEX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PMPEX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PMPEX
Annual income on $10K today (after 15% tax)
$1,103.90/yr
After 10yr DRIP, annual income (after tax)
$2,475.72/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, ABBV beats the other by $19,391.15/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PMPEX + ABBV for your $10,000?

PMPEX: 50%ABBV: 50%
100% ABBV50/50100% PMPEX
Portfolio after 10yr
$75.9K
Annual income
$14,319.16/yr
Blended yield
18.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

PMPEX
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PMPEX buys
0
ABBV buys
0
No recent congressional trades found for PMPEX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPMPEXABBV
Forward yield12.99%3.12%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$47.0K$104.7K
Annual income after 10y$2,912.61$25,725.73
Total dividends collected$20.8K$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PMPEX vs ABBV ($10,000, DRIP)

YearPMPEX PortfolioPMPEX Income/yrABBV PortfolioABBV Income/yrGap
1$11,999$1,298.70$11,559$438.51+$440.00PMPEX
2$14,295$1,456.33$13,494$640.86+$801.00PMPEX
3$16,917$1,621.53$15,951$945.97+$966.00PMPEX
4$19,895$1,793.43$19,152$1,413.89+$743.00PMPEX
5← crossover$23,258$1,971.12$23,443$2,146.38$185.00ABBV
6$27,040$2,153.63$29,391$3,321.96$2.4KABBV
7$31,273$2,340.00$37,948$5,265.87$6.7KABBV
8$35,991$2,529.26$50,795$8,596.74$14.8KABBV
9$41,231$2,720.43$71,034$14,549.41$29.8KABBV
10$47,030$2,912.61$104,715$25,725.73$57.7KABBV

PMPEX vs ABBV: Complete Analysis 2026

PMPEXStock

Functions as an open-end investment fund

Full PMPEX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this PMPEX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PMPEX vs SCHDPMPEX vs JEPIPMPEX vs OPMPEX vs KOPMPEX vs MAINPMPEX vs JNJPMPEX vs MRKPMPEX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.